FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Landry Robert E
2. Issuer Name and Ticker or Trading Symbol

REGENERON PHARMACEUTICALS, INC. [ REGN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP Finance CFO
(Last)          (First)          (Middle)

777 OLD SAW MILL RIVER ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

4/1/2020
(Street)

TARRYTOWN, NY 10591
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 4/2/2020  S(1)  69 D$495.24 (2)25092 D  
Common Stock 4/2/2020  S(1)  11 D$496.28 25081 D  
Common Stock 4/2/2020  S(1)  25 D$497.48 25056 D  
Common Stock 4/3/2020  S(1)  121 D$489.5 24935 D  
Common Stock 4/3/2020  S(1)  50 D$490.66 (3)24885 D  
Common Stock 4/3/2020  S(1)  25 D$492.76 24860 D  
Common Stock 4/3/2020  S(1)  99 D$493.51 (4)24761 D  
Common Stock 4/3/2020  S(1)  172 D$494.42 (5)24589 D  
Common Stock 4/3/2020  S(1)  2 D$495.56 24587 D  
Common Stock 4/3/2020  S(1)  54 D$496.33 24533 D  
Common Stock 4/3/2020  S(1)  25 D$497.6 (6)24508 D  
Common Stock 4/3/2020  S(1)  62 D$498.8 (7)24446 D  
Common Stock 4/3/2020  S(1)  73 D$499.37 (8)24373 D  
Common Stock         172 I By 401(k) Plan 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (right to buy) $272.7 4/1/2020  M (1)    2500   (9)9/9/2023 Common Stock 2500 $0.0 52000 D  
Non-Qualified Stock Option (right to buy) $272.7 4/1/2020  M (1)    2000   (9)9/9/2023 Common Stock 2000 $0.0 50000 D  
Non-Qualified Stock Option (right to buy) $272.7 4/1/2020  M (1)    1500   (9)9/9/2023 Common Stock 1500 $0.0 48500 D  
Non-Qualified Stock Option (right to buy) $272.7 4/2/2020  M (1)    3000   (9)9/9/2023 Common Stock 3000 $0.0 45500 (10)D  

Explanation of Responses:
(1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
(2) Represents volume-weighted average price of sales of 69 shares of Company stock on April 2, 2020 at prices ranging from $495.15 to $495.31. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price.
(3) Represents volume-weighted average price of sales of 50 shares of Company stock on April 3, 2020 at prices ranging from $490.45 to $490.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 3, 2020 at each separate price.
(4) Represents volume-weighted average price of sales of 99 shares of Company stock on April 3, 2020 at prices ranging from $493.02 to $493.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 3, 2020 at each separate price.
(5) Represents volume-weighted average price of sales of 172 shares of Company stock on April 3, 2020 at prices ranging from $494.01 to $494.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 3, 2020 at each separate price.
(6) Represents volume-weighted average price of sales of 25 shares of Company stock on April 3, 2020 at prices ranging from $497.35 to $497.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 3, 2020 at each separate price.
(7) Represents volume-weighted average price of sales of 62 shares of Company stock on April 3, 2020 at prices ranging from $498.77 to $498.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 3, 2020 at each separate price.
(8) Represents volume-weighted average price of sales of 73 shares of Company stock on April 3, 2020 at prices ranging from $499.09 to $499.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 3, 2020 at each separate price.
(9) The stock option award vests in four equal annual installments, commencing one year after the date of grant.
(10) Form two of two

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Landry Robert E
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591


EVP Finance CFO

Signatures
/s/**Robert E. Landry4/3/2020
**Signature of Reporting PersonDate

Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Regeneron Pharmaceuticals Charts.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Regeneron Pharmaceuticals Charts.